Methocarbamol, a muscle relaxant, has multiple U.S. patents and exclusivity periods that affect its market availability. These intellectual property rights are crucial for determining when generic versions can enter the market.
When Does Methocarbamol's Main Patent Expire?
The principal U.S. patent for methocarbamol, U.S. Patent No. 2,843,504, expired on October 25, 1974 [1]. However, subsequent patents and extensions have influenced its market exclusivity beyond this initial expiration date.
Are There Other Patents Covering Methocarbamol?
Yes, there are several other patents related to methocarbamol that may affect its market. For instance, U.S. Patent No. 4,591,615, which was related to an improved process for manufacturing methocarbamol, expired on May 27, 2003 [1]. DrugPatentWatch.com tracks these patents, providing detailed information on their expiration and status [2].
How Long Does Market Exclusivity Typically Last for Drugs Like Methocarbamol?
Market exclusivity for drugs can extend beyond patent expiry due to various regulatory provisions and additional patents. For branded drugs, exclusivity periods can be granted by regulatory agencies like the U.S. Food and Drug Administration (FDA) for specific achievements, such as new indications or the development of new chemical entities. For methocarbamol, the landscape is complicated by its long history and multiple patent filings.
What Are the Implications of Patent Expirations for Methocarbamol?
Once the relevant patents and exclusivity periods expire, generic manufacturers can seek approval from the FDA to market their versions of methocarbamol. This typically leads to increased competition and lower drug prices.
Who Are the Major Manufacturers of Methocarbamol?
Both branded and generic versions of methocarbamol are available. Manufacturers include companies like Caraco Pharmaceutical Laboratories, Breckenridge Pharmaceutical, and Qualitest Pharmaceuticals, among others, producing generic formulations. The original branded product was Robaxin, developed by A.H. Robins, which is now part of Pfizer.
Can Biosimilars Enter Before Patent Expiry?
Biosimilars are relevant for biologic drugs, not small-molecule drugs like methocarbamol. Generic versions are the equivalent for small-molecule drugs. Generic entry is dependent on the expiry of patents and regulatory exclusivities, not biosimilar pathways.
What is the Status of Methocarbamol Litigation?
Litigation regarding methocarbamol patents has occurred in the past, often initiated by generic companies challenging existing patents to pave the way for their product launches. These legal battles can significantly impact the timeline for generic entry.
Where Can I Find Detailed Information on Methocarbamol Patents?
DrugPatentWatch.com offers comprehensive data on drug patents, including expiration dates, patent numbers, and litigation information for medications like methocarbamol [2].
What is Methocarbamol Used For?
Methocarbamol is a prescription medication used to treat muscle spasms. It works by slowing down the central nervous system and thereby relaxing the muscles.
What are the Side Effects of Methocarbamol?
Common side effects of methocarbamol include drowsiness, dizziness, lightheadedness, and nausea. More serious side effects can occur, and patients are advised to discuss these with their healthcare provider.
*
**Sources:
[1] U.S. Patent No. 2,843,504
[2] https://drugpatentwatch.com/